Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial

被引:1
|
作者
Kiani, Zahra [1 ,2 ]
Khorsand, Nadereh [3 ]
Beigi, Fahimeh [4 ,5 ]
Askari, Gholamreza [1 ,2 ,6 ]
Sharma, Manoj [7 ]
Bagherniya, Mohammad [1 ,2 ,6 ]
机构
[1] Isfahan Univ Med Sci, Nutr & Food Secur Res Ctr, Sch Nutr & Food Sci, Esfahan, Iran
[2] Isfahan Univ Med Sci, Sch Nutr & Food Sci, Dept Community Nutr, Esfahan, Iran
[3] Isfahan Univ Med Sci, Imam Musa Kazem Hosp, Dept Internal Med, Esfahan, Iran
[4] Isfahan Univ Med Sci, Sch Pharm & Pharmaceut Sci, Pharmaceut Biotechnol Dept, Esfahan, Iran
[5] Isfahan Univ Med Sci, Imam Muss Kazim Hosp, Res & Dev Unit, Esfahan, Iran
[6] Isfahan Univ Med Sci, Anesthesia & Crit Care Res Ctr, Esfahan, Iran
[7] Univ Nevada, Sch Publ Hlth, Dept Social & Behav Hlth, Las Vegas, NV USA
关键词
Coenzyme Q10; Burn; Inflammation; Oxidative stress; FATTY LIVER-DISEASE; INFLAMMATORY MARKERS; OXIDATIVE STRESS; Q(10) SUPPLEMENTATION; METAANALYSIS; IMPROVES;
D O I
10.1186/s13063-024-08006-y
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background Burn injuries are important medical problems that, aside from skin damage, cause a systemic response including inflammation, oxidative stress, endocrine disorders, immune response, and hypermetabolic and catabolic responses which affect all the organs in the body. The aim of this study was to determine the effect of coenzyme Q10 (CoQ10) supplementation on inflammation, oxidative stress, and clinical outcomes in burn patients. Methods In a double-blind placebo-controlled randomized clinical trial, 60 burn patients were randomly assigned to receive 100 mg CoQ10 three times a day (total 300 mg/day) or a placebo for 10 days. Inflammatory markers including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), oxidative stress markers including total antioxidant capacity (TAC), malondialdehyde (MDA) and superoxide dismutase (SOD) activity, fasting blood glucose (FBG), blood urea nitrogen (BUN), creatinine, white blood cells (WBC), and body temperature were assessed as primary outcomes and albumin, prothrombin time (PT), partial thromboplastin time (PTT), international normalized ratio (INR), other hematological parameters, blood pressure, O-2 saturation, ICU duration, and 28-mortality rate were assessed as secondary outcomes. Results Fifty-two participants completed the trial. CRP and ESR levels were not significantly different between CoQ10 and placebo groups at the end of the study (P = 0.550 and P = 0.306, respectively). No significant differences between groups were observed for TAC (P = 0.865), MDA (P = 0.692), and SOD activity (P = 0.633) as well. Administration of CoQ10 resulted in a significant increase in albumin levels compared to placebo (P = 0.031). There was no statistically significant difference between the two groups in other measured outcomes (P > 0.05). Conclusion Results showed that in patients with burn injury, CoQ10 administration had no effect on inflammatory markers and oxidative stress, although serum albumin levels were improved after supplementation. Further studies with albumin as the primary outcome are needed to confirm this finding.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] A Randomized, Double-Blind, Placebo-Controlled Crossover Study of Coenzyme Q10 Therapy in Hypertensive Patients With the Metabolic Syndrome
    Young, Joanna M.
    Florkowski, Christopher M.
    Molyneux, Sarah L.
    McEwan, Roberta G.
    Frampton, Christopher M.
    Nicholls, M. Gary
    Scott, Russell S.
    George, Peter M.
    AMERICAN JOURNAL OF HYPERTENSION, 2012, 25 (02) : 261 - 270
  • [32] Effects of Coenzyme Q10 Supplementation on Exercise Performance and Markers of Oxidative Stress in Hemodialysis Patients: A Double-Blind Placebo-Controlled Crossover Trial
    Gokbel, Hakki
    Turk, Suleyman
    Okudan, Nilsel
    Atalay, Huseyin
    Belviranli, Muaz
    Gaipov, Abduzhappar
    Solak, Yalcin
    AMERICAN JOURNAL OF THERAPEUTICS, 2016, 23 (06) : E1736 - E1743
  • [33] Coenzyme Q10 in the Treatment of Heart Failure with Preserved Ejection Fraction: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial
    Tal Y. Samuel
    Tal Hasin
    Israel Gotsman
    Tanya Weitzman
    Fanny Ben Ivgi
    Ziv Dadon
    Elad Asher
    Offer Amir
    Michael Glikson
    Ronny Alcalai
    David Leibowitz
    Drugs in R&D, 2022, 22 : 25 - 33
  • [34] Coenzyme Q10 in the Treatment of Heart Failure with Preserved Ejection Fraction: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial
    Samuel, Tal Y.
    Hasin, Tal
    Gotsman, Israel
    Weitzman, Tanya
    Ben Ivgi, Fanny
    Dadon, Ziv
    Asher, Elad
    Amir, Offer
    Glikson, Michael
    Alcalai, Ronny
    Leibowitz, David
    DRUGS IN R&D, 2022, 22 (01) : 25 - 33
  • [35] Coenzyme Q10 Treatment in Infertile Men With Idiopathic Asthenozoospermia: A Placebo-Controlled, Double-Blind Randomized Trial Editorial Comment
    Niederberger, Craig
    JOURNAL OF UROLOGY, 2010, 183 (01): : 278 - 278
  • [36] Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie's disease: a double-blind, placebo-controlled randomized study
    Safarinejad, M. R.
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2010, 22 (05) : 298 - 309
  • [37] Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie's disease: a double-blind, placebo-controlled randomized study
    M R Safarinejad
    International Journal of Impotence Research, 2010, 22 : 298 - 309
  • [38] The effects of coenzyme Q10 supplementation on cardiometabolic markers in overweight type 2 diabetic patients with stable myocardial infarction: A randomized, double-blind, placebo-controlled trial
    Mirhashemi, Seyyed Mehdi
    Najafi, Vajiheh
    Raygan, Fariba
    Asemi, Zatollah
    ARYA Atherosclerosis, 2016, 12 (04) : 158 - 165
  • [39] Effects of coenzyme Q10 in PSP and CBD, a randomized, placebo-controlled, double-blind crossover pilot study
    Apetauerova, D.
    Lamont, S.
    Kakullavarapu, J.
    Scala, S.
    MOVEMENT DISORDERS, 2006, 21 : S526 - S527
  • [40] Coenzyme Q10 Terclatrate and Creatine in Chronic Heart Failure: A Randomized, Placebo-Controlled, Double-Blind Study
    Fumagalli, Stefano
    Fattirolli, Francesco
    Guarducci, Lorenzo
    Cellai, Tommaso
    Baldasseroni, Samuele
    Tarantini, Francesca
    Di Bari, Mauro
    Masotti, Giulio
    Marchionni, Niccolo
    CLINICAL CARDIOLOGY, 2011, 34 (04) : 211 - 217